Associated tags: Health care, Gedeon Richter, Central nervous system, Circulatory system, Scott Richter
Locations: HUNGARY, SWITZERLAND, AUSTRIA, BELGIUM, FRANCE, GERMANY, ITALY, NETHERLANDS, SPAIN, UNITED KINGDOM, UNITED STATES OF AMERICA, PORTUGAL, SWEDEN, ILLINOIS, LATVIA
Crave,
Disorder,
Congress,
European Psychiatric Association,
Gedeon Richter,
Poster,
DSM-IV codes,
Cariprazine,
Science,
Patient,
Scott Richter,
Observational study,
Medical diagnosis,
Caregiver,
Anxiety,
Mood,
Pharmaceutical industry The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder).
Key Points:
- The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder).
- Furthermore, a new transdiagnostic tool for quantifying, and visualizing symptom severity and functional disability of patients with different psychiatric conditions was presented.
- A special Gedeon Richter publication, the "Candid Book" was also introduced by the authors, which contains useful, everyday suggestions for the caregivers of patients.
- The final poster was providing information on the potential of cariprazine in dual disorder, the co-occurrence of a major psychiatric disorder and comorbid substance use disorder.
Retrieved on:
Wednesday, October 18, 2023
Cariprazine,
Hallucination,
Scott Richter,
Physician,
Asociality,
Observational study,
Alogia,
Patient,
ECNP,
Gideon,
Delusion,
Anhedonia,
European College of Neuropsychopharmacology,
Risperidone,
Woman,
Pharmaceutical industry,
Schizophrenia Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.
Key Points:
- Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.
- Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting about 1% of the population.
- Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
- Treatment with risperidone is still one of the most used standards when it comes to schizophrenia.
Retrieved on:
Thursday, October 5, 2023
Scott Richter,
Congress,
Safety,
Cariprazine,
Clozapine,
World Psychiatric Association,
TRS,
Gedeon Richter (company),
Gedeon Richter,
Patient,
Pharmaceutical industry,
Schizophrenia,
Psychiatry Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
Key Points:
- Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
- Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
- Cariprazine is a 3rd generation antipsychotic medication with a unique receptor profile and proven efficacy in persistent negative symptoms.
- At the Gedeon Richter and Recordati supported Meet-the-Expert session, Professor Christoph U. Correll talked about the activating-sedating effects of antipsychotics with special focus on cariprazine.
Retrieved on:
Wednesday, March 29, 2023
Depression,
Depression (mood),
Observational study,
Hospital,
Suicide,
Clinical trial,
Quality of life,
EPA,
Plasma,
Scott Richter,
DSM-IV codes,
Patient,
Risk,
Grammatical mood,
Diagnosis,
Poster,
Knowledge,
European Psychiatric Association,
Cariprazine,
Bipolar disorder,
Total,
Pharmaceutical industry,
TRR,
Schizophrenia Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
Key Points:
- Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
- Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
- Another poster highlighted the increasing need for gathering real-world data in order to understand how the drug works in heterogeneous patient populations, therefore complementing the knowledge gained from clinical trials.
- The 3rd poster provided details on the examination of the therapeutic reference range (TRR) for cariprazine 1.5 mg/day to 6 mg/day in schizophrenia studies.
Retrieved on:
Tuesday, February 14, 2023
Happiness,
Life,
Woman,
United Kingdom,
Family,
Diagnosis,
Dysmenorrhea,
COVID-19,
Birth,
Uterine fibroid,
Work,
Health,
Index,
Condom,
Menstrual cycle,
Pregnancy,
Quality of life,
Ageing,
Birth control,
Nursing While 82% thinks that they can provide security for the family, only 61% cares about the signals of their own body.
Key Points:
- While 82% thinks that they can provide security for the family, only 61% cares about the signals of their own body.
- Regular screenings are part of the everyday life of only one third, but women have been taking disease prevention more seriously.
- Having a healthy lifestyle and feeling attractive has become more important, while feeling balanced in their lives remained a major factor in determining women's wellbeing."
- Choosing safe contraception is the most important women's healthcare issue for the respondents, although 31% does not use any protection.
Retrieved on:
Tuesday, October 18, 2022
Akathisia,
Time,
Birth,
Female,
ECNP,
Woman,
Schizophrenia,
European College of Neuropsychopharmacology,
Patient,
Gedeon Richter,
Industry,
Polypharmacy,
Cariprazine,
Lists of diseases,
Incidence,
Product,
Clinical trial,
Scott Richter,
Pharmaceutical industry Issues regarding polypharmacy, and the special needs of women with schizophrenia were also highlighted in an industry-sponsored product theater and satellite symposium.
Key Points:
- Issues regarding polypharmacy, and the special needs of women with schizophrenia were also highlighted in an industry-sponsored product theater and satellite symposium.
- One of the poster presentations at ECNP authored by Professor Christoph U. Correll highlighted that the incidence of adverse drug reactions with cariprazine decreases over time.
- Furthermore, higher doses of cariprazine do not seem to increase neither rescue medication use nor extrapyramidal-related symptoms such as akathisia.
- Compared to previous treatment, patients with schizophrenia needed less rescue medications with cariprazine and experienced fewer side effects.
PNS,
Benzodiazepine,
EPA,
Prognosis,
Scott Richter,
Positive,
Hostility,
Cariprazine,
Positive and Negative Syndrome Scale,
Patient,
Poster,
Grammatical mood,
MADRS,
Population,
Lists of diseases,
Risperidone,
European Psychiatric Association,
Residential care,
Pharmaceutical industry,
Schizophrenia In the oral communication by Professor Christoph U. Correll, it was shown that benzodiazepines had no additive effects to cariprazine's efficacy, neither on total symptoms, nor on hostility.
Key Points:
- In the oral communication by Professor Christoph U. Correll, it was shown that benzodiazepines had no additive effects to cariprazine's efficacy, neither on total symptoms, nor on hostility.
- Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and affective symptoms, affecting 1% of the population.
- In addition, cariprazine without benzodiazepines significantly outperformed corresponding placebo in improving hostility symptoms.
- Patients from schizophrenia and bipolar depression studies were included in the analyses investigating cariprazine's potential in improving depressive symptoms.
('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.
Key Points:
- ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.
- The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development.
- AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA).
- AbbVie will have worldwide commercialization rights except for traditional markets of Richter, such as geographic Europe, Russia, other CIS countries and Vietnam.
Retrieved on:
Thursday, December 9, 2021
Osteoporosis,
Food,
Patient,
Osteoclast,
Cancer,
Partnership,
Osteosarcoma,
Bone metastasis,
Bone,
RANKL,
Fracture,
Bone loss,
Hikma,
Gideon,
China Biologic Products,
Scott Richter,
Cell,
Richter,
US Foods,
Fine chemical,
Pharmaceutical industry,
Health insurance ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement to commercialise Richter's denosumab, comprising two biosimilar products referencing Prolia and Xgeva("Products"), in the United States ("US").
Key Points:
- ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement to commercialise Richter's denosumab, comprising two biosimilar products referencing Prolia and Xgeva("Products"), in the United States ("US").
- Hikma is responsible for registering the Products with the US Food and Drug Administration and will have exclusive rights to commercialise them in the US.
- "We are looking forward to collaborating with Hikma on this important biosimilar project targeting the US market," said Gbor Orbn, Chief Executive Officer of Richter.
- Denosumab is a RANKL inhibitor which works by preventing the development of osteoclasts, which are cells that break down bone.
Psychiatry,
Branches of biology,
Psychology,
Psychiatric diagnosis,
Psychopathology,
Mood disorders,
Cariprazine,
Ureas,
Bipolar disorder,
Mental disorder,
Gedeon Richter,
Schizophrenia BUDAPEST, Hungary, July 7, 2021 /PRNewswire/ -- At the 15th World Congress of Biological Psychiatry, whichwas held virtually between the 28-30thJune 2021, Gedeon Richter Plc presented new analyses of cariprazine studies in form of two scientific posters and a free communication presentation.
Key Points:
- BUDAPEST, Hungary, July 7, 2021 /PRNewswire/ -- At the 15th World Congress of Biological Psychiatry, whichwas held virtually between the 28-30thJune 2021, Gedeon Richter Plc presented new analyses of cariprazine studies in form of two scientific posters and a free communication presentation.
- Gedeon Richter organised and sponsored a satellite symposium where knowledgeable psychiatrists discussed the unmet medical needs and cariprazine's efficacy in the treatment of bipolar disorder.
- Schizophrenia is a chronic psychiatric disorder that is comprised of positive, negative, and affective symptoms, as well as cognitive impairment.
- The illness affects about 1% of the population globally; and an estimated 5 million people struggle with this disorder in the EU.
